Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 261

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 261
---
 | May 2, 2018  |                     220,000 |                220,000 |                                           — | May 3, 2022                | May 3, 2028  |            65.84 |                                          |                                     51,216 |                     168,784 |
| Sanofi | Apr 30, 2019                    | Apr 30, 2019 |                     220,000 |                220,000 |                                           — | May 1, 2023                | Apr 30, 2029 |            76.71 |                                          |                                      6,600 |                     213,400 |

(a) Comprises the Chief Executive Officer, and any Deputy Chief Executive Officers or members of the Management Board in office at the date of grant. (b) In office at the date of grant. (c) Includes 293,812 options cancelled due to partial non-fulfillment of performance conditions. In 2024, 23,187 stock options were exercised by individuals who were Executive Committee members as of December 31, 2024. The plan involved post-dates the creation of the Executive Committee (Sanofi plan of March 5, 2014, exercise price €73.48). As of December 31, 2024, a total of 934,444 stock subscription options remained outstanding. As of the same date, 934,444 options were immediately exercisable. Existing Performance Share Plans as of December 31, 2024 The Board of Directors awards shares to certain employees in order to give them a direct stake in our future and performances via trends in the share price, as a partial substitute for the granting of stock options. Shares are awarded to employees by the Board of Directors on the basis of a list submitted to the Compensation Committee. The Board of Directors sets terms of the awards, including continuing employment conditions and performance conditions (measured over three financial years). The employee plans have a three-year vesting period, with no lock-up period. • At its meeting of April 30, 2024, the Board of Directors awarded a share performance plan, cascaded down into three sub-plans: – a plan under which 470 beneficiaries classified as “Senior Executives” were awarded a total of 1,394,478 shares; – a plan under which 8,234 beneficiaries not classified as “Senior Executives” were awarded a total of 2,888,502 shares; – a plan